Institution of second-line Estracyt therapy at an increase in PSA values for metastatic prostate cancer

Principal investigator

Per-Anders Abrahamsson (Denmark Knud Pedersen)

Patients

Tany,Nany,M1, PSP 0-1 (WHO 0-1 and Pain 0), Testosterone £ 1.0 nmol/ml, Life expectancy ³ 6 months with respond to first line hormone manipulation (PSA < 10 ng/ml or decrease by ³ 50%) and following this increase in PSA (PSA > 10 or ³ 50%)

Treatment

Estracyt 10 mg/kg acetylsalicylic acid 150 mg per day vs. placebo acetylsalicylic acid 150 mg per day

Inclusion period

1996 - 150398

Number of patients

48 (aim 230)

Sponsor

Pharmacia